Calcium-Rich Bone Environment Helps Osteosarcoma Cells Survive Chemotherapy

Chemotherapy for osteosarcoma, the most common bone cancer in children and young adults, often appears to succeed at first, only for the tumor to return months later in the same place. A new study offers a striking explanation for this pattern: the very chemistry of bone itself may be helping a small population of cancer cells survive the drug assault. Researchers report that the calcium-rich environment of bone fuels a signaling pathway that allows drug-tolerant persister cells, or DTP cells, to endure cisplatin, methotrexate, and doxorubicin by keeping their mitochondria in a protected, well-maintained state. The work, published in the Journal of Experimental & Clinical Cancer Research, identifies a chain of molecular events running from a calcium channel protein called ORAI3, through rising intracellular calcium, to the transcription factor NFAT4 and the mitophagy regulator PINK1, and it demonstrates that breaking this chain can dramatically reduce local tumor recurrence in animal models.

Drug-tolerant persister cells are a phenomenon increasingly recognized across many cancer types. These cells do not carry permanent resistance mutations; instead, they enter a reversible, slow-survival state that allows them to ride out treatment. Once chemotherapy stops, they can regrow into a full tumor, causing local recurrence that is often harder to treat than the original disease. In osteosarcoma, where aggressive multi-drug chemotherapy combined with surgery has improved survival significantly over past decades, relapse after apparently complete treatment remains a devastating clinical problem. The team behind the new study, led by researchers at the Eighth Affiliated Hospital of Sun Yat-sen University in Shenzhen, suspected that the unique biology of the bone microenvironment might be actively shaping this persister state rather than simply housing it.

The investigation began with a basic observation: when osteosarcoma cells were exposed to chemotherapy drugs in the laboratory, the surviving DTP cells showed consistently elevated levels of intracellular calcium. This finding immediately pointed toward the bone environment itself. Bone is, by definition, a mineral-rich tissue, saturated with calcium salts, and osteosarcoma cells live and evolve in that milieu. The researchers found that calcium buildup in persisting cells was accompanied by increased expression of ORAI3, a calcium channel protein involved in store-operated calcium entry, one of the main mechanisms by which cells replenish their internal calcium reserves. Elevated ORAI3 activity effectively opened the gates for calcium to flood into the persister cells, and that calcium flood turned out to be far from incidental.

Tracing the pathway downstream, the team showed that heightened calcium signaling promoted the nuclear translocation of NFAT4, a member of the nuclear factor of activated T cells family of transcription factors. Once inside the nucleus, NFAT4 acted on the gene encoding PINK1, PTEN-induced kinase 1, a well-known master regulator of mitophagy, the cellular process that identifies damaged mitochondria and directs their removal. In the persister cells, the result was a surge in PINK1-driven mitophagy. Rather than accumulating broken, dysfunctional mitochondria that would produce toxic reactive oxygen species and trigger cell death under chemotherapy stress, the DTP cells were continuously cleaning house, pruning away damaged mitochondria and preserving a pool of healthy ones.

The metabolic consequences of this mitochondrial quality control proved central to the survival strategy. Metabolic assays revealed that the persister cells maintained sustained tricarboxylic acid cycle activity and continued to rely on oxidative phosphorylation, the efficient mitochondrial process that generates cellular energy. This was a revealing finding, because many cancer cells under stress shift toward a less efficient, sugar-burning metabolism. The osteosarcoma persisters instead appeared to protect their oxidative powerhouses at all costs, and mitophagy was the mechanism that made this possible. By keeping mitochondrial homeostasis intact, the ORAI3–Ca²⁺–NFAT4–PINK1 axis ensured that the cells retained the energy production capacity needed to endure weeks of chemotherapeutic pressure without collapsing into metabolic failure.

To test whether this pathway mattered in living animals, the researchers engineered osteosarcoma xenografts carrying an inducible PINK1 knockdown system, allowing them to silence the gene at will. The results were striking in their timing. Before chemotherapy began, switching off PINK1 had no discernible effect on tumor growth; the cancer cells were perfectly viable. But once treatment started, tumors with silenced PINK1 showed reduced burden, and when chemotherapy was withdrawn, they regrew far more slowly than controls. In other words, PINK1 was not required for the tumor to exist, but it was essential for the tumor to survive chemotherapy and stage its comeback. Experiments in orthotopic bone tumors and lung metastasis models produced consistent results, reinforcing the conclusion that the pathway underpinned treatment tolerance across tumor settings.

The team then turned to pharmacological tools. GSK-7975 A, a small molecule that blocks ORAI-mediated calcium entry, proved capable of disrupting the axis at its source. Most notably, combining GSK-7975 A with chloroquine, an antimalarial drug that inhibits autophagic degradation, suppressed local recurrence in xenograft, orthotopic, and lung metastasis models. The logic of the combination is intuitive: the calcium channel blocker prevents the protective signal from being generated, while the autophagy inhibitor undermines the disposal machinery that persisters depend on. Together, the two agents deprived DTP cells of both the instruction and the equipment needed to maintain their mitochondrial shelter, leaving them vulnerable to chemotherapy they would otherwise survive.

Clinical evidence strengthened the case. Immunohistochemical analysis of human osteosarcoma tissues, comparing samples from patients who had received chemotherapy with those who had not, showed that ORAI3 and PINK1 expression was elevated after treatment, mirroring the laboratory findings. Single-cell and spatial transcriptomic analyses further supported the relevance of the axis in patient tumors, indicating that the calcium–mitophagy program is not merely a laboratory artifact but a feature of human disease. Given that both ORAI3 blockade and chloroquine-like compounds are already part of the pharmacological landscape, the pathway offers a plausible near-term target for clinical translation, potentially as an adjuvant strategy layered onto existing osteosarcoma chemotherapy regimens to eliminate the cells that seed recurrence.

The broader significance of the study lies in its reframing of the tumor microenvironment as an active participant in therapeutic failure. Rather than viewing recurrence simply as the outgrowth of resistant clones, the work suggests that bone’s defining biochemistry, its saturating calcium, hands osteosarcoma cells a ready-made survival program. It also connects two fields that rarely intersect: calcium channel biology and mitochondrial quality control, linked through NFAT4 as the molecular bridge. For a disease that disproportionately strikes adolescents and young adults, and where recurrence often carries a grim prognosis, the identification of a druggable axis that specifically disables persister cells during treatment represents a meaningful conceptual advance. If clinical studies confirm the animal findings, blocking ORAI3 or mitophagy could become a standard companion to chemotherapy, converting a treatment that currently leaves survivors vulnerable to relapse into one that clears the tumor down to its last resilient cell.

Subject of Research: A calcium-driven ORAI3–Ca²⁺–PINK1 mitophagy pathway that sustains drug-tolerant persister cells and local recurrence in osteosarcoma.

Article Title: Calcium-rich bone microenvironment promotes drug-tolerant persistence in osteosarcoma through ORAI3–Ca²⁺–PINK1–mitophagy axis

Article References: Li, H., Yu, H., Lu, Y., Liu, Y., Wu, W., Mi, R., Yang, W., Yuan, C., Yi, H., Gu, Y., Zhuang, J., & Ma, M. (2026). Calcium-rich bone microenvironment promotes drug-tolerant persistence in osteosarcoma through ORAI3–Ca²⁺–PINK1–mitophagy axis. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03828-x

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03828-x

Keywords: osteosarcoma, drug-tolerant persister cells, calcium signaling, ORAI3, PINK1, mitophagy, NFAT4, oxidative phosphorylation, local recurrence, chemotherapy, GSK-7975 A, chloroquine